Antifungal Agents. Polyenes Azoles Allyl and Benzyl Amines Other antifungals

Size: px
Start display at page:

Download "Antifungal Agents. Polyenes Azoles Allyl and Benzyl Amines Other antifungals"

Transcription

1 OPTO 6434 General Pharmacology Antifungal Agents Dr. Alison McDermott Room 254 HBSB, Phone Fall 2015 Reading: Chapter 50 Brody s Human Pharmacology by Wecker et al. 5 th edn. Polyenes Azoles Allyl and Benzyl Amines Other antifungals 1. Fungi and Fungal Infections (Mycoses) Less common than bacterial/viral infections Some cause disease in otherwise healthy humans most ONLY when host defences reduced e.g. loss of mechanical barrier, immunosuppression, diabetes Most dermatological and just unsightly but if systemic can be life-threatening e.g. mortality rate for invasive candida 30-50% Typically requires long term therapy (weeks to months) Examples of infection (see diagram p2) 1

2 2

3 2. Polyenes Amphotericin B, Nystatin, Natamycin Macrocyclic lactones with hydrophobic and hydrophilic regions Bind to ergosterol and form pores which make the fungal cell leaky Resistance: replacement of ergosterol by precursors Amphotericin B Active against candida, aspergillus, cryptococcus, coccidioidomyces, sporothrix, histoplasma, blastomyces. Formulations: (a) mixed with deoxycholate for IV (e.g. Fungizone) Side effects high% renal toxicity, fever, headache, normochromic normocytic anaemia (b) complexed with lipids (e.g. Abelcet) IV, much less renal toxicity than cholate formulation Side effects - fever & chills Interactions: with anti-neoplastic drugs leads to renal toxicity, with corticosteroids causes cardiac dysfunction Nystatin Topical For cutaneous/mucocutaneous and oral Candida Natamycin Active against candida, aspergillus, fusarium and others 5% ophthalmic suspension (Natacyn) for blepharitis, conjunctivitis & keratitis 3

4 3. Azoles Imidazoles (2 N) and triazoles (3N) Triazoles are most recent, are metabolised more slowly and are more specific for fungi Inhibit sterol 14-α-demethylase no ergosterol; 14-α-methylsterols build up and disturb cell membrane. squalene squalene epoxide lanosterol ergosterol X Resistance due to over-production of demethylase, or mutated demethylase Systemic Azoles: Fluconazole (e.g. Diflucan) Ketoconazole (e.g. Nizoral) Itraconazole (e.g. Sporanox) Voriconazole (e.g. Vfend, also used off-label topically for fungal keratitis) Posaconazole (Noxafil) For serious infections: systemic candidiasis, cryptococcus etc.. Fluconazole crosses blood brain barrier Side effects: Minor: headache, neausea, abdominal pain. Major: hepatic toxicity & anaphylaxis Voriconazole may cause visual disturbances Drug interactions: Reduced cyclosporine clearance renal toxicity Serious cardiac problems with e.g. cisapride (antacid), triazolam (anti-insomnia) Topical Azoles e.g. ketoconazole, econazole, terconazole For superficial and cutaneous infections Many available OTC Side effects: redness, stinging, itching 4

5 4. Allyl and Benzyl Amines Inhibit squalene epoxidase (squalene to squalene epoxide) no ergosterol squalene squalene epoxide lanosterol ergosterol X Naftifine (Naftin) & Butenafine (Mentax) Topical only for ringworm (tinea corporis etc) Side-effects redness, itchiness, dryness Terbinafine (Lamisil) Topical for ringworm (tinea corporis etc) Oral for Tinea unguium, side effects: GI upset, liver test abnormalities, rash 5. Other systemic antifungals Flucytosine (Ancobon) Antimetabolite that interferes with DNA synthesis Griseofulvin (Grifulvin) Blocks microtubule formation so inhibits cell division Echinocandins Caspofungin acetate (Cancidas), Anidulafungin (Eraxis), Micafungin (Mycamine) Inhibit glucan synthase and hence synthesis of B 1,3 D- glucans which are essential cell wall components 5

6 Antifungals : Overview Uses: Topical application Level of infection (cream, oral suspension powder, etc..) Superficial (e.g. versicolor) Azoles NA Systemic (Oral or IV) Cutaneous Dermatophyte (e.g. tinea pedis) Candida (skin/mucus membrane) Azoles Allyl and benzyl amines Azoles Polyenes Allyl and benzyl amines (terbinafine) Griseofulvin Azoles (Itraconazole) Azoles (fluconazole, Ketoconazole) Subcutaneous (e.g. sporothrix) NA Azoles (itraconazole) Amphotericin B Systemic (e.g. histoplasma, candida) NA Amphotericin B Flucytosine Azoles (Fluconazole, Itraconazole, Ketoconazole, Voriconazole, Posaconazole) Echinocandins Modes of Action 6

Antifungal drugs Dr. Raz Muhammed

Antifungal drugs Dr. Raz Muhammed Antifungal drugs 13. 12. 2018 Dr. Raz Muhammed 2. Flucytosine (5-FC) Is fungistatic Is a synthetic pyrimidine antimetabolite Is often used in combination with amphotericin B in the treatment of systemic

More information

Fungi are eukaryotic With rigid cell walls composed largely of chitin rather than peptidoglycan (a characteristic component of most bacterial cell

Fungi are eukaryotic With rigid cell walls composed largely of chitin rather than peptidoglycan (a characteristic component of most bacterial cell Antifungal Drugs Fungal infections (Mycoses) Often chronic in nature. Mycotic infections may be superficial and involve only the skin (cutaneous mycoses extending into the epidermis) Others may penetrate

More information

Antimycotics. November 14, Jan Strojil. Ústav farmakologie LF UP

Antimycotics. November 14, Jan Strojil. Ústav farmakologie LF UP Ústav farmakologie LF UP November 14, 2005 Introduction Polyens Azoles Alylamines Other Outline Introduction Polyens Azoles Alylamines and morfolines Other Introduction Polyens Azoles Alylamines Other

More information

ANTIMYCOTIC DRUGS Modes of Action

ANTIMYCOTIC DRUGS Modes of Action ANTIMYCOTIC DRUGS Modes of Action Prapasarakul Nuvee, D.V.M., Ph.D. Department of Veterinary Microbiology, Faculty of Veterinary Science, Chulalongkorn University 1 What drugs act as antifungal agents?

More information

Form 2046 R3.0: Fungal Infection Pre-HSCT Date

Form 2046 R3.0: Fungal Infection Pre-HSCT Date Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous

More information

PHARMACEUTICAL CHEMISTRY II (PHCM672) Lecture 1, Antifungal Drugs (Antimycotics) Dr. Mohammad Abdel-Halim

PHARMACEUTICAL CHEMISTRY II (PHCM672) Lecture 1, Antifungal Drugs (Antimycotics) Dr. Mohammad Abdel-Halim PHARMACEUTICAL CHEMISTRY II (PHCM672) Lecture 1, Antifungal Drugs (Antimycotics) Dr. Mohammad Abdel-Halim Chemotherapeutic agents Pharmaceutical Chemistry I Antibacterial drugs Pharmaceutical Chemistry

More information

Biochemical Targets for Antifungal Chemotherapy

Biochemical Targets for Antifungal Chemotherapy Biochemical Targets for Antifungal Chemotherapy Fungal cells are complex organisms that share many biochemical targets with other eukaryotic cells. Therefore, agents that interact with fungal targets not

More information

Antifungal Drugs 35 I. OVERVIEW II. DRUGS FOR SUBCUTANEOUS AND SYSTEMIC MYCOTIC INFECTIONS

Antifungal Drugs 35 I. OVERVIEW II. DRUGS FOR SUBCUTANEOUS AND SYSTEMIC MYCOTIC INFECTIONS Antifungal Drugs 35 I. OVERVIEW Infectious diseases caused by fungi are called mycoses, and they are often chronic in nature. 1 Some mycotic infections are superficial and some involve the skin (cutaneous

More information

Pharmaceutical Chemistry II. Antifungal Agents. = Antimycotics. Tutorial 1

Pharmaceutical Chemistry II. Antifungal Agents. = Antimycotics. Tutorial 1 Pharmaceutical Chemistry II Antifungal Agents = Antimycotics Tutorial 1 1) Give examples of some common fungal infections indicating whether they are rather superficial or systemic. Fungal infections Tinea

More information

Fungal Infection Pre-Infusion Data

Fungal Infection Pre-Infusion Data Fungal Infection Pre-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: Event date: / / CIBMTR Form 2046 revision 5 (page 1 of 5). Last Updated May, 2018. Infection Episode

More information

Antifungal Agents. Prof. Suheil Zmeili Faculty of Medicine Department of Pharmacology University of Jordan

Antifungal Agents. Prof. Suheil Zmeili Faculty of Medicine Department of Pharmacology University of Jordan Antifungal Agents Prof. Suheil Zmeili Faculty of Medicine Department of Pharmacology University of Jordan Antifungal Agents Objectives: - Know Available antifungal drugs - Know their MOA - Know their Pharmacokinetic

More information

ANTIFUNGAL AGENTS. Alison Clode, DVM, DACVO. Port City Veterinary Referral Hospital Portsmouth, New Hampshire

ANTIFUNGAL AGENTS. Alison Clode, DVM, DACVO. Port City Veterinary Referral Hospital Portsmouth, New Hampshire ANTIFUNGAL AGENTS Alison Clode, DVM, DACVO Port City Veterinary Referral Hospital Portsmouth, New Hampshire New England Equine Medical and Surgical Center Dover, New Hampshire Overview Fungal organisms

More information

Biochemical Targets for Antifungal Chemotherapy

Biochemical Targets for Antifungal Chemotherapy Biochemical Targets for Antifungal Chemotherapy Fungal cells are complex organisms that share many biochemical targets with other eukaryotic cells. Therefore, agents that interact with fungal targets not

More information

(Notes on Anti-TB agents are included in the TB syllabus)

(Notes on Anti-TB agents are included in the TB syllabus) (Notes on Anti-TB agents are included in the TB syllabus) Antifungal Agents A. Zuger MD General background: 1. Fungi are eukaryotes, with more cellular similarities to human cells than to bacterial cells.

More information

Fungal Infection Post-Infusion Data

Fungal Infection Post-Infusion Data Fungal Infection Post-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: Event date: / / Visit: 100 day 6 months 1 year 2 years >2 years. Specify: CIBMTR Form 2146 revision

More information

Course content. Chemotherapeutic agents

Course content. Chemotherapeutic agents Course content 1 Chemotherapeutic agents Mechanism of actions Indications Contraindications/Cautions Drug interactions Side-effects/Adverse reactions Dosage regimen (occasionally) Reference Books 2 Pharmacology

More information

About the Editor Gerri S. Hall, Ph.D.

About the Editor Gerri S. Hall, Ph.D. About the Editor Gerri S. Hall, Ph.D. Dr. Hall s professional career has been focused on clinical microbiology: direct clinical activities of various areas such as bacteriology, mycobacteria, STD testing,

More information

Improving Clinical Outcomes in Fungal Infection Control and Management

Improving Clinical Outcomes in Fungal Infection Control and Management Improving Clinical Outcomes in Fungal Infection Control and Management DISCLAIMER The information within this CME/CE activity is for continuing education purposes only, and is not intended to substitute

More information

THE TREATMENT OF MYCOSES IN REPTILES: A REVIEW OF ANTIFUNGAL DRUGS

THE TREATMENT OF MYCOSES IN REPTILES: A REVIEW OF ANTIFUNGAL DRUGS THE TREATMENT OF MYCOSES IN REPTILES: A REVIEW OF ANTIFUNGAL DRUGS Jean A. Paré, DMV, DVSc, Dipl ACZM Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin, 2015 Linden

More information

Med Chem 401: Mycology (www.doctorfungus.org) Mycology

Med Chem 401: Mycology (www.doctorfungus.org) Mycology Med Chem 401: Mycology (www.doctorfungus.org) Mycology is the Study of Fungi (Monera, Protoctista, Fungi, Plantae, Animalia). Fungi are eukaryotic cells and as such contain nuclei, mitochondria, ER, golgi,

More information

SUSCEPTIBILITY PROFILE OF EMERGING FUNGAL PATHOGENS

SUSCEPTIBILITY PROFILE OF EMERGING FUNGAL PATHOGENS SUSCEPTIBILITY PROFILE OF EMERGING FUNGAL PATHOGENS Professor Lia Monica JUNIE, Department of Microbiology, University of Medicine and Pharmacy, Cluj Napoca, Romania The most common fungal pathogens are:

More information

Management of fungal infection

Management of fungal infection Management of fungal infection HKDU symposium 17 th May 2015 Speaker: Dr. Thomas Chan MBBS (Hons), MRCP, FHKCP, FHKAM Synopsis Infection caused by fungus mycoses Skin infection by fungus is common in general

More information

Antimicrobials; antibacterials, antifungals, antiprotozoans, antivirals, and antihelminthics 6

Antimicrobials; antibacterials, antifungals, antiprotozoans, antivirals, and antihelminthics 6 Antimicrobials; antibacterials, antifungals, antiprotozoans, antivirals, and antihelminthics 6 Inhibition of Ergosterol Synthesis Azoles Miconazole Triazoles Allylamines For azole-resistant infections

More information

Special features. For personal use only. Not to be reproduced without permission of the editor

Special features. For personal use only. Not to be reproduced without permission of the editor Special features For personal use only. Not to be reproduced without permission of the editor (permissions@pharmj.org.uk) Fungal infections pharmacological therapy Treatment of fungal infections is developing

More information

Ali Alabbadi. Sarah Jaar ... Nader

Ali Alabbadi. Sarah Jaar ... Nader 24 Ali Alabbadi Sarah Jaar... Nader Intro to Mycology *underlined text was explained in the lecture but is not found in the slides -mycology: the study of the mycoses of man (fungal infections) -less than

More information

Antifungals, antivirals, antiprotozoals, and anthelmintics

Antifungals, antivirals, antiprotozoals, and anthelmintics Antifungals, antivirals, antiprotozoals, and anthelmintics Joseph K. Ritter, PhD Asst. Prof Department of Pharmacology and Toxicology MSB Room 530 jritter@hsc.vcu.edu Difficulties associated with treatment

More information

Chapter 18. Fungal Diseases of the Lung. Mosby items and derived items 2011, 2006 by Mosby, Inc., an affiliate of Elsevier Inc.

Chapter 18. Fungal Diseases of the Lung. Mosby items and derived items 2011, 2006 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 18 Fungal Diseases of the Lung 1 YLS S M AC Figure 18-1. Fungal disease of the lung. Cross-sectional view of alveoli infected with Histoplasma capsulatum. AC, alveolar consolidation; M, alveolar

More information

Updated Guidelines for Management of Candidiasis. Vidya Sankar, DMD, MHS April 6, 2017

Updated Guidelines for Management of Candidiasis. Vidya Sankar, DMD, MHS April 6, 2017 Updated Guidelines for Management of Candidiasis Vidya Sankar, DMD, MHS April 6, 2017 Statement of Disclosure I have no actual or potential conflict of interest in relation to this presentation Outline

More information

C. albicans C. tropicalis C. parapsilosis C. kefyr C. glabrata C. krusei C. guillermondii C. lusitaniae THERAPY USING ANTIFUNGALS AND ANTIVIRALS

C. albicans C. tropicalis C. parapsilosis C. kefyr C. glabrata C. krusei C. guillermondii C. lusitaniae THERAPY USING ANTIFUNGALS AND ANTIVIRALS THERAPY USING ANTIFUNGALS AND ANTIVIRALS Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu CLASSIFICATION OF FUNGI Yeasts Candida Cryptococcus

More information

MANAGEMENT OF PULMONARY MYCOSIS

MANAGEMENT OF PULMONARY MYCOSIS MANAGEMENT OF PULMONARY MYCOSIS Eva Van Braeckel, MD, PhD Dpt. of Respiratory Medicine UZ Gent PENTALFA KU Leuven 03.03.2016 MANAGEMENT OF PULMONARY MYCOSIS 1. Antifungals 1. Acute invasive pulmonary aspergillosis

More information

LUZU (luliconazole) external cream

LUZU (luliconazole) external cream LUZU (luliconazole) external cream Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage

More information

Antifungal therapies differences in agents

Antifungal therapies differences in agents Antifungal therapies differences in agents The basic Fungi are eukaryotes Eukaryote = an organism whose cells contain complex structures enclosed within membrane. Most Common Fungal Pathogens Dermatophytes

More information

Clinical Practice Guideline Superficial Fungal Infection

Clinical Practice Guideline Superficial Fungal Infection Clinical Practice Guideline Superficial Fungal Infection ก ก ก กก ก ก ก ก กก ก ก ก ก ก ก ก ก ก ก ก ก ก ก ก ก ก ก * ก Superficial fungal infection ก 1. ก (Pityriasis versicolor, Tinea versicolor) 2. ก ก

More information

Itraconazole DIGICON. Composition: MOLECULAR INTRODUCTION

Itraconazole DIGICON. Composition: MOLECULAR INTRODUCTION Itraconazole DIGICON Composition: Itraconazole 100 mg MOLECULAR INTRODUCTION Itraconazole is a triazole medicine used to treat fungal infections. It is effective against a broad spectrum of fungi including:

More information

Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong

Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases Y.L. Kwong Department of Medicine University of Hong Kong Pathogenic yeast Candida Cryptococcus Trichosporon Pathogenic

More information

Chapter III ANTIVIRAL AND ANTIFUNGAL DRUGS

Chapter III ANTIVIRAL AND ANTIFUNGAL DRUGS Chapter III ANTIVIRAL AND ANTIFUNGAL DRUGS AN OUNCE OF PREVENTION WORTH POUND OF CURE Year III Pharm.D Dr. V. Chitra ANTIVIRAL DRUGS Viruses are small(20-30 nm) infective agents that are incapable of reproduction

More information

Current Options in Antifungal Pharmacotherapy

Current Options in Antifungal Pharmacotherapy Current Options in Antifungal Pharmacotherapy John Mohr, Pharm.D., Melissa Johnson, Pharm.D., Travis Cooper, Pharm.D., James S. Lewis, II, Pharm.D., and Luis Ostrosky-Zeichner, M.D. Infections caused by

More information

Pharmacogenomics of Antifungal Agents

Pharmacogenomics of Antifungal Agents Chapter 38 Pharmacogenomics of Antifungal Agents H.R. Ashbee a and M.H. Gilleece b a Mycology Reference Centre, Department of Microbiology, Leeds Teaching Hospitals NHS Trust, UK, b Department of Haematology,

More information

Medical Management of Fungal Sinusitis

Medical Management of Fungal Sinusitis ISSN: 2250-0359 Volume 3 Supplement 2 2013 Medical Management of Fungal Sinusitis *Balasubramanian Thiagarajan *Geetha Ramamoorthy *Stanley Medical College Abstract: Medical therapy constitutes an useful

More information

Antifungal Update. Candida: In Vitro Antifungal Susceptibility Testing

Antifungal Update. Candida: In Vitro Antifungal Susceptibility Testing Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood

More information

Drugs dermatological conditions II

Drugs dermatological conditions II MMS Pharmacology Lecture 5 Drugs dermatological conditions II Dr Sura Al Zoubi 1 TOPICAL CORTICOSTEROIDS Corticosteroids (glucocorticoids) have immunosuppressive and antiinflammatory properties. Topical

More information

Antifungal Update 2/22/12. Which is the most appropriate initial empirical therapy in a candidemic patient?

Antifungal Update 2/22/12. Which is the most appropriate initial empirical therapy in a candidemic patient? Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco 3/3 blood cultures are positive for an unidentified

More information

Antifungal resistance mechanisms in pathogenic fungi

Antifungal resistance mechanisms in pathogenic fungi Antifungal resistance mechanisms in pathogenic fungi Shivaprakash M Rudramurthy Additional Professor, Mycology Division Center of Advanced Research in Medical Mycology, National Culture Collection of Pathogenic

More information

Antifungal Update 2/24/11. Which is the most appropriate initial empirical therapy in a candidemic patient?

Antifungal Update 2/24/11. Which is the most appropriate initial empirical therapy in a candidemic patient? Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author How To Best Use Antifungal Agents Cornelia Lass-Flörl Division of Hygiene and Medical Microbiology Innsbruck Medical University ESCMID SUMMER SCHOOL 2012 Epidemiology Diagnosis Roadmap Antifungal drugs

More information

number Done by Corrected by Doctor د.حامد الزعبي

number Done by Corrected by Doctor د.حامد الزعبي number Fungi#1 Done by نرجس الس ماك Corrected by مهدي الشعراوي Doctor د.حامد الزعبي Introduction to Mycology -Terms: -Medical Mycology: The study of mycosis and their etiological agents -Mycosis: Disease

More information

An Update in the Management of Candidiasis

An Update in the Management of Candidiasis An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College

More information

البيض بالمبيضات الحفاظي الجلد التهاب = candidiasis Diaper

البيض بالمبيضات الحفاظي الجلد التهاب = candidiasis Diaper 1 / 26 Candidiasis Candida albicans is the most common cause of human candidal infections, 1 but other pathogenic species include Candida glabrata, Candida parapsilosis, Candida tropicalis, Candida krusei,

More information

NEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS. 20th Symposium (spring 2003) Thursday May 22nd 2003

NEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS. 20th Symposium (spring 2003) Thursday May 22nd 2003 NEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATINS 20th Symposium (spring 2003) Thursday May 22nd 2003 The slides presented at this meeting are available on this site as "Web slide shows" and

More information

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory ZODERM E CREAM. Oxiconazole Nitrate Cream

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory ZODERM E CREAM. Oxiconazole Nitrate Cream For the use only of Registered Medical Practitioners or a Hospital or a Laboratory ZODERM E CREAM Oxiconazole Nitrate Cream QUALITATIVE AND QUANTITATIVE COMPOSITION ZODERM E CREAM contains: Oxiconazole

More information

Use of Antifungals in the Year 2008

Use of Antifungals in the Year 2008 Use of Antifungals in the Year 2008 Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine Diagnosis

More information

Antifungal Pharmacotherapy

Antifungal Pharmacotherapy Interpreting Antifungal Susceptibility Testing: Science or Smoke and Mirrors A. W. F O T H E R G I L L, M A, M B A U N I V E R S I T Y O F T E X A S H E A L T H S C I E N C E C E N T E R S A N A N T O

More information

Updates and practical guide on antifungal agents

Updates and practical guide on antifungal agents Updates and practical guide on antifungal agents Dr Atul Patel, MD, FIDSA Chief Consultant and Director Infectious Diseases Clinic Vedanta Institute of Medical Sciences Ahmedabad, India Presented at MMTN

More information

Dermatophytie = ﺔﻔﻌﺳ ﺔﻴرﻄﻓ

Dermatophytie = ﺔﻔﻌﺳ ﺔﻴرﻄﻓ 1 / 20 2 / 20 3 / 20 4 / 20 dermatophytes The and superficial belong dermatophytes to the Several and forms. adeep of This dermatophytes of article fungi focuses (ringworm) infect on superficial humans;

More information

Condition First line Alternative Comments Candidemia Nonneutropenic adults

Condition First line Alternative Comments Candidemia Nonneutropenic adults Recommendations for the treatment of candidiasis. Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. Condition First line Alternative

More information

Fungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia

Fungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554

More information

Review of Newer Antifungal and Immunomodulatory Strategies for Invasive Aspergillosis

Review of Newer Antifungal and Immunomodulatory Strategies for Invasive Aspergillosis SUPPLEMENT ARTICLE Review of Newer Antifungal and Immunomodulatory Strategies for Invasive Aspergillosis William J. Steinbach 1 and David A. Stevens 2 1 Division of Pediatric Infectious Diseases, Department

More information

Sumyuktha J., Murali Narasimhan*, Parveen Basher Ahamed

Sumyuktha J., Murali Narasimhan*, Parveen Basher Ahamed International Journal of Research in Dermatology Sumyuktha J et al. Int J Res Dermatol. 2017 Mar;3(1):59-63 http://www.ijord.com Original Research Article DOI: http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20170082

More information

Current options of antifungal therapy in invasive candidiasis

Current options of antifungal therapy in invasive candidiasis Current options of antifungal therapy in invasive candidiasis Saloua Ladeb Bone Marrow Transplant Center Tunis HAMMAMET 24 th April 2012 DEFINITION One or more positive results on blood culture for Candida

More information

Deep Dermatophytosis

Deep Dermatophytosis Deep Dermatophytosis 2016-11-06 MMTN/Bangkok Department of Dermatology Chang Gung Memorial Hospital, Linkou Branch Taoyuan, Taiwan Superficial dermatophytosis Wikimedia Stratum corneum Tinea faciei Tinea

More information

Mycology. Dr. Agoston Ghidan

Mycology. Dr. Agoston Ghidan Mycology Dr. Agoston Ghidan 27.10.2014. Fungi are eukaryotic cells each fungal cell has: nucleus and nuclear membrane endoplasmic reticulum mitochondria most fungi are obligate or facultative aerobes most

More information

Common Fungi. Catherine Diamond MD MPH

Common Fungi. Catherine Diamond MD MPH Common Fungi Catherine Diamond MD MPH Birth Month and Day & Last Four Digits of Your Cell Phone # BEFORE: http://tinyurl.com/kvfy3ts AFTER: http://tinyurl.com/lc4dzwr Clinically Common Fungi Yeast Mold

More information

CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR

CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS Dr AMIT RAODEO DM SEMINAR Introduction The incidence of invasive fungal infections in critically ill intensive

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...

More information

B. Incorrect! Peginterferon α-2a is used for the treatment of chronic hepatitis B and may be preferable to interferon- α.

B. Incorrect! Peginterferon α-2a is used for the treatment of chronic hepatitis B and may be preferable to interferon- α. Pharmacology - Problem Drill 24: Antibiotics, Antifungal and Antiviral Drugs Question No. 1 of 10 1. reduces the replication of influenza A and B viruses by inhibiting viral neuraminidase. Question #01

More information

ZYGOMYCOSIS: AN UPDATE ON TREATMENT OPTIONS

ZYGOMYCOSIS: AN UPDATE ON TREATMENT OPTIONS Volume 24, Issue 4 January 2009 ZYGOMYCOSIS: AN UPDATE ON TREATMENT OPTIONS Erin Brady, Pharm.D. Candidate Zygomycosis, also referred to as Mucormycosis, is a rare angioinvasive fungal infection caused

More information

Antifungal resistance in Aspergillus fumigatus

Antifungal resistance in Aspergillus fumigatus Antifungal resistance in Aspergillus fumigatus Dr Lily Novak Frazer and Dr Caroline Moore University of Manchester at the Manchester Academic Health & Science Centre and the Mycology Reference Centre,

More information

The incidence of invasive fungal infections

The incidence of invasive fungal infections AN EPIDEMIOLOGIC UPDATE ON INVASIVE FUNGAL INFECTIONS * Michael A. Pfaller, MD ABSTRACT *Based on a presentation given by Dr Pfaller at a symposium held in conjunction with the 43rd Interscience Conference

More information

Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles

Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles and Others}, Polyenes {Amphotericin B, Candicidin, Hamycin,

More information

Medicinal Chemistry I II nd Module Special Section (3) Major Antifungal Drugs

Medicinal Chemistry I II nd Module Special Section (3) Major Antifungal Drugs Medicinal Chemistry I II nd Module Special Section (3) Major Antifungal Drugs The Ideal Antifungal Agent Over the last 50 years, there has been a sustained effort to discover and develop an ideal treatment

More information

Abstract. OBJECTIVE--To compare the efficacy and safety of terbinafine 1% cream and clotrimazole 1% cream in the treatment of tinea pedis.

Abstract. OBJECTIVE--To compare the efficacy and safety of terbinafine 1% cream and clotrimazole 1% cream in the treatment of tinea pedis. Abstract. OBJECTIVE--To compare the efficacy and safety of terbinafine 1% cream and clotrimazole 1% cream in the treatment of tinea pedis. DESIGN-- Multicentre, double blind parallel group study. SETTING--32

More information

Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences

Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences 5th MMTN Conference 5-6 November 2016 Bangkok, Thailand 10:20-10:45, 6 Nov, 2016 Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences Yee-Chun Chen, M.D., PhD. Department of Medicine,

More information

Introduction. Yeast candida, cryptococcus, trichosporon. Filamentous rhizopus, rhizomucor, mucor. Dimorphic Fungi bl t hi t l

Introduction. Yeast candida, cryptococcus, trichosporon. Filamentous rhizopus, rhizomucor, mucor. Dimorphic Fungi bl t hi t l Presenter Vikas Naik Moderator Aditya Gupta Deepak Gupta Introduction Fungi are saphrophytes Yeast candida, cryptococcus, trichosporon Filamentous rhizopus, rhizomucor, mucor Dimorphic Fungi bl t hi t

More information

MENINGITIS CRYPTOCOCCAL. learn about the symptoms, diagnosing and treating this disease

MENINGITIS CRYPTOCOCCAL. learn about the symptoms, diagnosing and treating this disease CRYPTOCOCCAL MENINGITIS learn about the symptoms, diagnosing and treating this disease A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS JANAURY 2007 Cryptococcal

More information

Malaria prevention: source = The Sanford Guide to Antimicrobial Therapy. Gilbert et al.

Malaria prevention: source = The Sanford Guide to Antimicrobial Therapy. Gilbert et al. Malaria prevention: Agent Adult dose a Contraindications Application Notes Atovaquoneproguanil 250/100mg x1/day Insufficient data in pregnancy Prophylaxis for areas with CQ resistance, 2 expensive with

More information

Review Article Antifungal Resistance and New Strategies to Control Fungal Infections

Review Article Antifungal Resistance and New Strategies to Control Fungal Infections indawi Publishing Corporation International Journal of Microbiology Volume 2012, Article ID 713687, 26 pages doi:10.1155/2012/713687 Review Article Antifungal Resistance and ew Strategies to Control Fungal

More information

ITRANOX. Composition Each capsule contains :

ITRANOX. Composition Each capsule contains : ITRANOX Composition Each capsule contains : Itraconazole 100 mg Capsules Action Itraconazole is a synthetic triazole derivative. When administered orally, it has shown fungistatic activity against superficial

More information

What have we learned about systemic antifungals currently available on the market?

What have we learned about systemic antifungals currently available on the market? 2nd ECMM/CEMM Workshop Milano, September 25, 2010 What have we learned about systemic antifungals currently available on the market? Prof. Dr. Georg Maschmeyer Dept. of Hematology, Oncology & Palliative

More information

Rheem Totah, Office H172M, Ph Office hours MWF 11:30 12:20 or by arrangement

Rheem Totah, Office H172M, Ph Office hours MWF 11:30 12:20 or by arrangement Rheem Totah, Office H172M, Ph 206-543-9481 rtotah@uw.edu Office hours MWF 11:30 12:20 or by arrangement Date/Time Topic Readings Mon March 26 Antifungal agents Foye s Chapter 40 Wed March 28 Antifungal

More information

Fungal Infection in the ICU: Current Controversies

Fungal Infection in the ICU: Current Controversies Fungal Infection in the ICU: Current Controversies Andrew F. Shorr, MD, MPH, FCCP, FACP Washington Hospital Center Georgetown University, Washington, DC Disclosures I have served as a consultant to, researcher/investigator

More information

A COMPARATIVE STUDY OF EFFICACY OF TERBINAFINE AND FLUCONAZOLE IN PATIENTS OF TINEA CORPORIS

A COMPARATIVE STUDY OF EFFICACY OF TERBINAFINE AND FLUCONAZOLE IN PATIENTS OF TINEA CORPORIS Int. J. Pharm. Med. & Bio. Sc. 2013 Kumar Amit et al., 2013 Research Paper ISSN 2278 5221 www.ijpmbs.com Vol. 2, No. 4, October 2013 2013 IJPMBS. All Rights Reserved A COMPARATIVE STUDY OF EFFICACY OF

More information

Three clinical cases. fungal infections

Three clinical cases. fungal infections Three clinical cases Diagnostic and treatment challenges in skin and mucosal fungal infections Else Svejgaard, MD, Merete Hædersdal, MD Dept. of Dermatology, Bispebjerg University Hospital, Copenhagen,

More information

Voriconazole. Voriconazole VRCZ ITCZ

Voriconazole. Voriconazole VRCZ ITCZ 7 7 8 7 8 fluconazole itraconazole in vitro in vivo Candida spp. C. glabrata C. krusei Cryptococcus neoformans in vitro Aspergillus spp. in vitro in vivo Aspergillus fumigatus Candida albicans C. krusei

More information

Antifungals and Anti-Tuberculosis Agents

Antifungals and Anti-Tuberculosis Agents Antifungals and Anti-Tuberculosis Agents Christine Kubin, Pharm.D.,., BCP Clinical Pharmacist, Infectious Diseases NewYork-Presbyterian Hospital Columbia University Medical Center Antifungal Agents 1 Fungi

More information

1. Multiple choice (30 2 each); circle the number of the correct choice. b. Trichophyton schoenleinii is traditionally most associated with

1. Multiple choice (30 2 each); circle the number of the correct choice. b. Trichophyton schoenleinii is traditionally most associated with NAME SS# EXAM 2 March 26, 2002 BIO 329 Directions: All explanations, definitions, and descriptions should be presented in good English This means complete sentences should be used except when lists or

More information

Pharmacology of Antifungal Drugs in Newborns- Rio de Janeiro August 2014

Pharmacology of Antifungal Drugs in Newborns- Rio de Janeiro August 2014 Pharmacology of Antifungal Drugs in Newborns- Rio de Janeiro August 2014 J.V. Aranda, MD,PhD,FRCPC,FAAP Professor and Director of Neonatology and NIH- New York Pediatric Developmental Pharmacology Research

More information

TOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR

TOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR TOWARDS PRE-EMPTIVE? GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% TRADITIONAL DIAGNOSIS β-d-glucan Neg Predict Value 100% PCR diagnostics FUNGAL BURDEN FIRST TEST POSITIVE FOR ASPERGILLOSIS

More information

TINEA (FUNGAL) INFECTION

TINEA (FUNGAL) INFECTION 1 Medical Topics - Tinea TINEA (FUNGAL) INFECTION Tinea infection There are 3 main groups of fungal organisms that can cause skin infections. They include dermatophytes, yeast and moulds. Dermatophytes

More information

Review article J Bas Res Med Sci 2018; 5(2):48-55.

Review article J Bas Res Med Sci 2018; 5(2):48-55. Antifungal agents: Polyene, azole, antimetabolite, other and future agents Fardin Ali Malayeri 1, Ali Akbar Rezaei 2, Omid Raiesi 3* 1. Department of Clinical Biochemistry, Faculty of Medicine, Zabol University

More information

Fungal Infections. Alessandro Diana November 22th 2007

Fungal Infections. Alessandro Diana November 22th 2007 Fungal Infections Alessandro Diana November 22th 2007 alessandro.diana@ne.ch Topics Aspergillosis Candidiasis Cryptococcosis Histoplasmosis Coccidioidomycosis Blastomyocosis Sporotrichosis Pneumocystis

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author What is the best antifungal strategy for severe intra-abdominal infections? Philippe Montravers MD, PhD Anaesthesia and Surgical ICU Bichat Claude Bernard Hospital Assistance Publique Hopitaux de Paris

More information

IJBCP International Journal of Basic & Clinical Pharmacology

IJBCP International Journal of Basic & Clinical Pharmacology Print ISSN 2319-2003 Online ISSN 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology doi: 10.18203/2319-2003.ijbcp20150020 Research Article Efficacy safety of 1% terbinafine hydrochloride

More information

Update zu EUCAST 2012 Cornelia Lass-Flörl

Update zu EUCAST 2012 Cornelia Lass-Flörl Update zu EUCAST 2012 Cornelia Lass-Flörl Frühjahrstagung 2012 Paul-Ehrlich-Gesellschaft Sektion Antimykotische Chemotherapie Bonn, 4./5. Mai 2012 Agenda 1. Breakpoints 2. Rationale documents and technical

More information

Optimizing antifungal dosing regimens. Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology

Optimizing antifungal dosing regimens. Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology ATHENA 2017 International Conference November 28 30, 2017 Optimizing antifungal dosing regimens Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology Clinical Microbiology Laboratory, «Attikon»

More information

DISEASES OF FUNGAL ORIGIN

DISEASES OF FUNGAL ORIGIN DISEASES OF FUNGAL ORIGIN Fungi are eukaryotes with cell walls that give them their shape. Fungal cells can grow as a multicellular filaments called moulds Or as single cells or chains of cells called

More information

Therapeutic Drug Monitoring in Antifungal Therapy. Why, When and How

Therapeutic Drug Monitoring in Antifungal Therapy. Why, When and How Therapeutic Drug Monitoring in Antifungal Therapy Why, When and How Roger Brüggemann Radboud University Nijmegen Medical Centre and Nijmegen Institute for Infection, Inflammation and Immunology (N4i) Trends

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 5 March 2008

The legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 5 March 2008 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 5 March 2008 ECALTA 100 mg, powder and solvent for concentrate for solution for infusion Box containing 1 30 ml glass

More information

Tinea Infection, an Encumbrance of the Year

Tinea Infection, an Encumbrance of the Year International Journal of Clinical Chemistry and Laboratory Medicine (IJCCLM) Volume 4, Issue 1, 2018, PP 9-13 ISSN No. (Online) 2455-7153 DOI: http://dx.doi.org/10.20431/2455-7153.0401003 www.arcjournals.org

More information

WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?

WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,

More information